BIOQUAL, Inc. Appoints Hanne Andersen Elyard as Chief Scientific Officer
May 09, 2022 at 01:03 pm EDT
Share
BIOQUAL, Inc. announced Creation of the Role of Chief Scientific Officer and appointment of Hanne Andersen Elyard, PhD, as the Initial Chief Scientific Officer. In her role as Chief Scientific Officer, Dr. Elyard will oversee BIOQUAL's in-vivo and in-vitro contract research and development effort. Dr. Elyard will join the company's executive leadership team.
In January 2006 she joined BIOQUAL as a staff scientist, was promoted to Research Director in 2010, and subsequently promoted to Vice President of Science in 2018.
Bioqual, Inc. is engaged in performing contract research services, which is focused on in vivo models of human diseases, including COVID-19, acquired immune deficiency syndrome (AIDS), influenza, Mpox, respiratory syncytial virus (RSV) infection, Flavivirus infections, including zika and dengue, malaria, hepatitis, and cancer. It is involved in the evaluation of vaccines, vaccine therapeutics, microbicides, and drug therapies. The Company also performs in vitro contract research services. The in vitro services include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation and other cell-based assays. It also provides research services in herpes simplex in rodents, filariasis in rhesus macaques, chikungunya in rodents and macaques and dengue in rodents and macaques.